Mayo Clinic developed an AI that analyzes routine pathology slides to classify meningiomas and predict recurrence risk, reducing dependency on advanced genetic testing.
Key Details
- 1Study published in The Lancet Digital Health by Mayo Clinic researchers.
- 2AI models analyze standard H&E slides to classify meningiomas and predict recurrence.
- 3Approach relies on images already used in clinical care, not on expensive genetic tests.
- 4Dataset included tissue samples, images, and clinical data from 672 patients.
- 5AI predictions remained valuable beyond traditional clinical factors like tumor grade or patient age.
- 6Further prospective studies are needed before routine clinical adoption.
Why It Matters
This work shows how imaging AI can extend the power of pathology slides, making advanced tumor insights more universally accessible even where genetic testing isn't available. It holds promise for improved, personalized cancer care using existing imaging workflows.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.